Valsartan Recall Expands: Mylan Recalls Over 100 Lots

Pharmaceutical company Mylan is recalling some of its blood pressure medications due to cancer concerns. The medications recalled all contain Valsartan. Since July 2018, the FDA has been recalling Valsartan due to finding trace amounts of N-nitrosodimethylamine (NDMA) and N-nitrosodiethylamine (NDEA), which are classified as probable human carcinogens by the Environmental Protection Agency.

Mylan has recalled a total of 119 lots of medication containing Valsartan, including Amlodipine and Valsartan Tablets, Valsartan Tablets, and Hydrochlorothiazide Tablets. The list of all recalled lots can be found here.

This is the largest recall in FDA history. Mylan joins a growing number of companies that have recalled lots that contain Valsartan, Irbesartan, and Losartan due to carcinogen contamination. GoldenbergLaw is committed to holding these pharmaceutical companies accountable. If you or a loved one has taken Valsartan, Irbesartan, or Losartan and have been diagnosed with cancer, contact GoldenbergLaw.

Losartan Recalled: List of Recalled Sartan Drugs Continues to Grow

On November 9, 2018, the FDA issued a recall of Losartan due to carcinogen contamination concerns. Losartan is now the third “sartan” drug that has been recalled after the carcinogen N-Nitrosodiethylamine (NDEA) was detected in its active pharmaceutical ingredient.

The recalled lots of Losartan were manufactured by Zhejiang Huahai Pharmaceutical Co. Ltd., the same company that manufactured the NDMA-contaminated Valsartan. Since then, the FDA has put Zhejiang Huahai Pharmaceutical on an import alert, meaning the FDA “has enough evidence to allow for Detention Without Physical Examination of products that appear to be in violation of FDA laws and regulations.”

NDEA is a probable human carcinogen and can cause:

  • Liver cancer
  • Kidney cancer
  • Pancreatic cancer
  • Stomach cancer
  • Colon/colorectal/intestinal cancer
  • Bladder cancer

If you or a loved one contracted liver, kidney, pancreatic, stomach, colorectal, or bladder cancer after taking Losartan, contact GoldenbergLaw. Leave the sleepless nights to us.

 

Will There Be a Sartan Drug Recall?

After learning about the Valsartan recall due to contamination, many patients were switched from Valsartan to other sartan drugs. But now many are questioning the safety of these sartan drugs after learning that the European Medicines Agency (EMA) is investigating candesartan, irbesartan, losartan, and olmesartan for the same reason. It’s only a matter of time before the EMA and FDA determine if there should be a sartan drug recall.

The EMA announced that low levels of N-nitrosodiethylamine (NDEA) were detected in losartan, prompting the precautionary investigation into other sartan drugs because of the similar chemical structure. “National authorities in the EU are currently considering whether to recall medicines containing Aurobindo Pharma’s irbesartan from pharmacies as a precaution,” the EMA said.

The EMA will be increasing supervision on Chinese company Zheijiang Huahai to review the manufacturing process of other active substances. The investigation will help the European Commission to determine if there should be a sartan drug recall.

If the European Union decides to issue a sartan drug recall, the FDA may follow suit. GoldenbergLaw will continue to update on the Valsartan and sartan investigation.

If you or a loved one took Valsartan and was diagnosed with liver, colorectal, stomach, pancreatic, kidney or bladder cancer, please contact us. We have successfully resolved similar cases, including many involving the high blood pressure medication Benicar. Call GoldenbergLaw, and leave the sleepless nights to us.

Talk With Us >